143 related articles for article (PubMed ID: 37793761)
21. Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study.
Lonial S; Lee HC; Badros A; Trudel S; Nooka AK; Chari A; Abdallah AO; Callander N; Sborov D; Suvannasankha A; Weisel K; Voorhees PM; Womersley L; Baron J; Piontek T; Lewis E; Opalinska J; Gupta I; Cohen AD
Cancer; 2021 Nov; 127(22):4198-4212. PubMed ID: 34314018
[TBL] [Abstract][Full Text] [Related]
22. Uveal effusion syndrome secondary to belantamab mafodotin in a patient treated for refractory myeloma.
Dupré R; Gastaud L; Rocher F; Baillif S; Martel A
J Fr Ophtalmol; 2022 Jan; 45(1):e5-e6. PubMed ID: 34384623
[No Abstract] [Full Text] [Related]
23. Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study.
Richardson PG; Lee HC; Abdallah AO; Cohen AD; Kapoor P; Voorhees PM; Hoos A; Wang K; Baron J; Piontek T; Byrne J; Richmond S; Jewell RC; Opalinska J; Gupta I; Lonial S
Blood Cancer J; 2020 Oct; 10(10):106. PubMed ID: 33097687
[TBL] [Abstract][Full Text] [Related]
24. Updates in the management of relapsed/refractory multiple myeloma.
Hanna KS; Larson S; Nguyen J; Tu S; Boudreau J; Rose S
J Oncol Pharm Pract; 2021 Sep; 27(6):1477-1490. PubMed ID: 34162244
[TBL] [Abstract][Full Text] [Related]
25. Longitudinal efficacy and safety modeling and simulation framework to aid dose selection of belantamab mafodotin for patients with multiple myeloma.
Collins J; van Noort M; Rathi C; Post TM; Struemper H; Jewell RC; Ferron-Brady G
CPT Pharmacometrics Syst Pharmacol; 2023 Oct; 12(10):1411-1424. PubMed ID: 37465991
[TBL] [Abstract][Full Text] [Related]
26. Characterization of response and corneal events with extended follow-up after belantamab mafodotin (GSK2857916) monotherapy for patients with relapsed multiple myeloma: a case series from the first-time-in-human clinical trial.
Popat R; Warcel D; O'Nions J; Cowley A; Smith S; Tucker WR; Yong K; Esposti SD
Haematologica; 2020 May; 105(5):e261-e263. PubMed ID: 32107339
[No Abstract] [Full Text] [Related]
27. High response rates with single-agent belantamab mafodotin in relapsed systemic AL amyloidosis.
Khwaja J; Bomsztyk J; Mahmood S; Wisniowski B; Shah R; Tailor A; Yong K; Popat R; Rabin N; Kyriakou C; Sive J; Esposti SD; Larkin DFP; Worthington S; Hart A; Dowling E; Correia N; Bygrave C; Rydzewski A; Jamroziak K; Wechalekar AD
Blood Cancer J; 2022 Sep; 12(9):128. PubMed ID: 36064540
[No Abstract] [Full Text] [Related]
28. Belantamab mafodotin induces immunogenic cell death within 24 h post-administration in newly diagnosed multiple myeloma patients.
Kostopoulos IV; Kakalis A; Birmpilis A; Angelis N; Orologas-Stavrou N; Rousakis P; Panteli C; Gavriatopoulou M; Kastritis E; Dimopoulos MA; Tsitsilonis O; Terpos E
Am J Hematol; 2023 Mar; 98(3):E65-E67. PubMed ID: 36565455
[No Abstract] [Full Text] [Related]
29. Population pharmacokinetics of belantamab mafodotin, a BCMA-targeting agent in patients with relapsed/refractory multiple myeloma.
Rathi C; Collins J; Struemper H; Opalinska J; Jewell RC; Ferron-Brady G
CPT Pharmacometrics Syst Pharmacol; 2021 Aug; 10(8):851-863. PubMed ID: 34076364
[TBL] [Abstract][Full Text] [Related]
30. [Occurrence of corneal microcystoid alterations under administration of belantamab mafodotin for multiple myeloma].
Zimmermann J; Esser E; Eter N; Schütt P; Uhlig CE
Ophthalmologie; 2023 Jul; 120(7):747-750. PubMed ID: 35943529
[No Abstract] [Full Text] [Related]
31. Explosive Disease Progression After Single-Agent B-cell Maturation Antigen-Targeted Treatment in Multiple Myeloma: A Report of Three Cases in Sheikh Shakhbout Medical City.
Jaber W; Abdaljalil A; Ali A; Abu Haleeqa M; Mheidly K
Cureus; 2023 Aug; 15(8):e44433. PubMed ID: 37791224
[TBL] [Abstract][Full Text] [Related]
32. [Iatrogenic keratopathy secondary to multiple myeloma treatment with belantamab mafodotin].
Menardais B; Soethoudt M; Espargillière D; Mouriaux F
J Fr Ophtalmol; 2021 May; 44(5):766-768. PubMed ID: 33454122
[No Abstract] [Full Text] [Related]
33. Long-lasting effect of belantamab mafodotin in heavily pretreated multiple myeloma.
Gil-Sierra MD; Briceño-Casado MDP; Julia-Luna FJ; Martinez-Moya MD
Indian J Pharmacol; 2022; 54(5):373-376. PubMed ID: 36537407
[TBL] [Abstract][Full Text] [Related]
34. Patient-reported experiences during and following treatment with belantamab mafodotin for relapsed/refractory multiple myeloma in the DREAMM-2 study.
Cardellino A; Correll JR; Martin M; Gorsh B; Sapra S; Popat R
Front Oncol; 2023; 13():1274659. PubMed ID: 38144529
[TBL] [Abstract][Full Text] [Related]
35. Hepatic Veno-occlusive disease (VOD) in multiple myeloma patient receiving Belantamab Mafodotin.
Pessach I; Argyrakopoulou G; Petropoulos F; Rapti I; Danglis F; Trajce E; Chandrinou E
Leuk Lymphoma; 2023 Apr; 64(4):904-906. PubMed ID: 36794387
[No Abstract] [Full Text] [Related]
36. DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma.
Prawitz T; Popat R; Suvannasankha A; Sarri G; Hughes R; Wang F; Hogea C; Ferrante SA; Gorsh B; Willson J; Kapetanakis V
Adv Ther; 2021 Nov; 38(11):5501-5518. PubMed ID: 34561812
[TBL] [Abstract][Full Text] [Related]
37. Belantamab mafodotin detection by MASS-FIX and immunofixation.
Mellors PW; Kohlhagen MC; Dasari S; Willrich MAV; Gertz MA; Kumar SK; Lacy MQ; Murray DL; Dispenzieri A
Clin Chem Lab Med; 2021 Oct; 59(11):e430-e433. PubMed ID: 34114387
[No Abstract] [Full Text] [Related]
38. Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma.
Rodriguez-Otero P; Ayers D; Cope S; Davies FE; Delforge M; Mojebi A; Jansen JP; Weisel K; Hege K; Dhanasiri S
Leuk Lymphoma; 2021 Oct; 62(10):2482-2491. PubMed ID: 33896344
[TBL] [Abstract][Full Text] [Related]
39. Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM).
Lonial S; Nooka AK; Thulasi P; Badros AZ; Jeng BH; Callander NS; Potter HA; Sborov D; Zaugg BE; Popat R; Degli Esposti S; Byrne J; Opalinska J; Baron J; Piontek T; Gupta I; Dana R; Farooq AV; Colby K; Jakubowiak A
Blood Cancer J; 2021 May; 11(5):103. PubMed ID: 34039952
[TBL] [Abstract][Full Text] [Related]
40. Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma.
Weisel K; Krishnan A; Schecter JM; Vogel M; Jackson CC; Deraedt W; Yeh TM; Banerjee A; Yalniz F; Nesheiwat T; Van Sanden S; Diels J; Valluri S; Usmani SZ; Berdeja JG; Jagannath S; Martin T
Clin Lymphoma Myeloma Leuk; 2022 Sep; 22(9):690-701. PubMed ID: 35764490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
